(888) 352-RUSH for help arranging an appointment.
Faculty Rank: Professor
Medical or Graduate Education:
Loyola University Chicago Stritch School of Medicine
Boston University - Surgery
National Cancer Institute - Surgical Oncology
Cancer surgery, skin
Sentinel lymph node biopsy
Soft tissue tumors
Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.
Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Mosenson JA, Zloza A, Nieland JD, Garrett-Mayer E, Eby JM, Huelsmann EJ, Kumar P, Denman CJ, Lacek AT, Kohlhapp FJ, Alamiri A, Hughes T, Bines SD, Kaufman HL, Overbeck A, Mehrotra S, Hernandez C, Nishimura MI, Guevara-Patino JA, Le Poole IC. Sci Transl Med. 2013 2013 Feb 27 5(174):174ra28. doi: 10.1126/scitranslmed.3005127. Recursive SVM biomarker selection for early detection of breast cancer in peripheral blood. Zhang F, Kaufman HL, Deng Y, Drabier R. BMC Med Genomics. 2013 2013 6 Suppl 1:S4. doi: 10.1186/1755-8794-6-S1-S4. Epub 2013 Jan 23. Clinical and safety profile of high-dose interleukin-2 treatment in elderly patients with metastatic melanoma and renal cell carcinoma. Clark JM, Kelley B, Titze J, Fung H, Maciejewski J, Nathan S, Rich E, Basu S, Kaufman HL. Oncology. 2013 2013 84(2):123-6. doi: 10.1159/000342764. Epub 2012 Dec 7. Vaccines for melanoma and renal cell carcinoma. Kaufman HL. Semin Oncol. 2012 2012 Jun 39(3):263-75. doi: 10.1053/j.seminoncol.2012.02.011. Review. TroVax vaccine therapy for renal cell carcinoma. Zhang RT, Bines SD, Ruby C, Kaufman HL. Immunotherapy. 2012 2012 Jan 4(1):27-42. doi: 10.2217/imt.11.160. Review. First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. Berinstein NL, Karkada M, Morse MA, Nemunaitis JJ, Chatta G, Kaufman H, Odunsi K, Nigam R, Sammatur L, MacDonald LD, Weir GM, Stanford MM, Mansour M. J Transl Med. 2012 2012 Aug 3 10:156. doi: 10.1186/1479-5876-10-156. An association between corticosteroid use and melanoma recurrence: a case report and review of the literature. Lazarus M, Kaufman H. Med Oncol. 2011 Sep 16 Vaccines for colorectal cancer and renal cell carcinoma. Kabaker K, Shell K, Kaufman HL. Cancer J. 2011 Sep 17(5):283-93 doi: 10.1097/PPO.0b013e318232ff44. Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression. Xu X, Rao GS, Groh V, Spies T, Gattuso P, Kaufman HL, Plate J, Prinz RA. BMC Cancer. 2011 May 23 11(1):194. doi: 10.1186/1471-2407-11-194. MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients Harrop R, Shingler WH, McDonald M, Treasure P, Amato RJ, Hawkins RE, Kaufman HL, de Belin J, Kelleher M, Goonewardena M, Naylor S Cancer Immunol Immunother 2011 Mar 9 gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra KL, White RL, Gonzalez R, Kuzel TM, Curti B, Leming PD, Whitman ED, Balkissoon J, Reintgen DS, Kaufman H, Marincola FM, Merino MJ, et al. N Engl J Med. 2011 Jun 2 364(22):2119-27. Statistical methods on detecting differentially expressed genes for RNA-seq data. Chen Z, Liu J, Ng HK, Nadarajah S, Kaufman HL, Yang JY, Deng Y. BMC Syst Biol. 2011 2011 Dec 23 5 Suppl 3:S1. doi: 10.1186/1752-0509-5-S3-S1. Epub 2011 Dec 23. Single-incision laparoscopic surgery for intra-abdominal metastatic melanoma. Turner J, Myers JA, Titze J, Kaufman HL, Bines SD. Am Surg. 2011 Aug 77(8):164-5 An update on TroVax for the treatment of progressive castration-resistant prostate cancer. Abern M, Kaufman HL, Latchamsetty K. Onco Targets Ther. 2011 4:33-41 TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: Lessons learned and future development Kim DW, Krishnamurthy V, Bines SD, Kaufman HL Hum Vaccin 2010 Oct 1 6(10):12-19 Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study Amato RJ, Hawkins RE, Kaufman HL, Thompson JA, Tomczak P, Szczylik C, McDonald M, Eastty S, Shingler WH, de Belin J, Goonewardena M, Naylor S, Harrop R Clin Cancer Res 2010 Nov 15 16(22):5539-47 Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S Ann Surg Oncol 2010 Mar 17(3):718-30 OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma Kaufman HL, Bines SD Future Oncol 2010 Jun 6(6):941-9 Herpes simplex virus oncolytic vaccine therapy in melanoma Sivendran S, Pan M, Kaufman HL, Saenger Y Expert Opin Biol Ther 2010 Jul 10(7):1145-53 Imaging the immune response to monitor tumor immunotherapy Wang Q, Ornstein M, Kaufman HL Expert Rev Vaccines 2009 Oct 8(10):1427-37 Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand Kim HS, Kim-Schulze S, Kim DW, Kaufman HL Cancer Res 2009 Nov 1 69(21):8516-25 Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy Sabatino M, Kim-Schulze S, Panelli MC, Stroncek D, Wang E, Taback B, Kim DW, Deraffele G, Pos Z, Marincola FM, Kaufman HL J Clin Oncol 2009 Jun 1 27(16):2645-52 Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma Kaufman HL, Taback B, Sherman W, Kim DW, Shingler WH, Moroziewicz D, DeRaffele G, Mitcham J, Carroll MW, Harrop R, Naylor S, Kim-Schulze S J Transl Med 2009 Jan 7 7:2 Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment Kim-Schulze S, Kim HS, Fan Q, Kim DW, Kaufman HL Mol Ther 2009 Feb 17(2):380-8 A therapeutic cancer vaccine targeting carcinoembryonic antigen in intestinal carcinomas Mori F, Giannetti P, Peruzzi D, Lazzaro D, Giampaoli S, Kaufman HL, Ciliberto G, La Monica N, Aurisicchio L Hum Gene Ther 2009 Feb 20(2):125-36 Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, Gonzalez R, Glaspy J, Whitman E, Harrington K, Goldsweig H, Marshall T, Love C, Coffin R, Nemunaitis JJ J Clin Oncol 2009 Dec 1 27(34):5763-71 Gene therapy for antitumor vaccination Kim-Schulze S, Kaufman HL Methods Mol Biol 2009 542:515-27 Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy Ugurel S, Schrama D, Keller G, Schadendorf D, Bröcker EB, Houben R, Zapatka M, Fink W, Kaufman HL, Becker JC Cancer Immunol Immunother 2008 May 57(5):685-91 Activation of Rho kinase by TNF-alpha is required for JNK activation in human pulmonary microvascular endothelial cells Mong PY, Petrulio C, Kaufman HL, Wang Q J Immunol 2008 Jan 1 180(1):550-8 Intrarectal vaccination with recombinant vaccinia virus expressing carcinoembronic antigen induces mucosal and systemic immunity and prevents progression of colorectal cancer Kim-Schulze S, Kim HS, Wainstein A, Kim DW, Yang WC, Moroziewicz D, Mong PY, Bereta M, Taback B, Wang Q, Kaufman HL J Immunol 2008 Dec 1 181(11):8112-9 Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer Kaufman HL, Lenz HJ, Marshall J, Singh D, Garett C, Cripps C, Moore M, von Mehren M, Dalfen R, Heim WJ, Conry RM, Urba WJ, Benson AB 3rd, Yu M, Caterini J, Kim-Schulze S, Debenedette M, Salha D, Vogel T, Elias I, Berinstein NL Clin Cancer Res 2008 Aug 1 14(15):4843-9
To watch a brief video of Howard L. Kaufman, MD, click the play button at the lower left corner of the video frame below.
(If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
I think this is a really exciting time to be a cancer physician, because we’ve never had more new options for patients. And so this spans the realm from preventing the cancers in the first place, to identifying them at earlier and earlier stages, to developing new treatments that are more effective. And what we often do with our patients is — once we’ve cured them of their cancer, we know that they’re still at a high risk for other problems in the future. And we try to really take care of them, and get them into an established prevention and screening program, so that if things progress in any way that we catch them early, and we can intervene at a time when we can be more effective.